The association between out-of-pocket costs and adherence to adjuvant endocrine therapy among newly diagnosed breast cancer patients

Albert J. Farias, PhD, MPH[1], **Ryan N. Hansen, PhD**[2], **Steven B. Zeliadt, PhD**[3,4], **India Ornelas, PhD**[3], **Christopher Li, MD, PhD**[5,6], and **Beti Thompson, PhD**[3,6]

[1]Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas Health Sciences Center at Houston, School of Public Health, Houston, TX USA

[2]Department of Pharmacy, University of Washington, Seattle, WA USA

[3]Department of Health Services, University of Washington, Seattle, WA USA

[4]Health Services Research and Development Center of Excellence, Department of Veterans Affairs Puget Sound Health Care System, Seattle, WA USA

[5]Department of Epidemiology, University of Washington, Seattle, WA USA

[6]Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA USA

Abstract

Objective—To determine how out-of-pocket costs for adjuvant endocrine therapy (AET) medication affects adherence among newly diagnosed breast cancer survivors with private health insurance who initiate therapy.

Methods—We examined medical and pharmacy claims for the 1-year period after initiating AET using the Truven Health Analytics MarketScan® database. Adherence was defined as 80% proportion of days covered (PDC). Mean out-of-pocket costs for AET fill were measured as the sum of copayments, coinsurance, and deductibles and adjusted to 30-day amounts. Using a multivariable logistic regression model we calculated adjusted risk ratios controlling for age, comorbidities, type of surgery, use of chemotherapy and/or radiation therapy, average out-of-pocket costs for other services, and pharmacy use characteristics.

Results—Of the 6,863 women 64 years and younger who were diagnosed with breast cancer and initiated AET, 73.9% were adherent (PDC 80%). A total of 19% of patients had less than $5 monthly out-of-pocket costs for AET, 30% had $5–$9.99, 17% had $10–14.99, 10% had $15–19.99, and 25% had $20 or greater. Patients with out-of-pocket costs for AET between $10–14.99, $15–$19.99, and greater than $20 were 6–8% less likely to be adherent compared to patients paying less than $5.00, after controlling for covariates (p<0.05). Out-of-pocket costs for inpatient, outpatient, and other pharmacy services were not associated with adherence.

Corresponding author: Albert Farias, Department of Epidemiology and Human Genetics, University of Texas Health Sciences Center at Houston School of Public Health, 1200 Pressler St, Suite E633, Houston, TX 77030, Phone: (626) 393-1634, Fax: (206) 667-5977, afarias@uw.edu.

Conclusion—A substantial proportion of privately insured patients are non-adherent to AET and out-of-pocket costs for AET medication are significantly associated with a greater likelihood of non-adherence.

Keywords

Adherence; Adjuvant Endocrine Therapy; Breast Cancer; Out-of-pocket costs

INTRODUCTION

Estrogen receptor-positive (ER+) breast cancer is present in two-thirds of breast cancer cases in the US.[1,2] In addition to a combination of surgery, chemotherapy and/or radiation, the standard of care for ER+ breast cancer for post-menopausal women is endocrine therapy with third generation aromatase inhibitors (AI) such as exemestane, anastrozole, or letrozole for 5 years.[3–6] Similarly, the National Comprehensive Cancer Network (NCCN) at the time of the study period recommended that pre-menopausal women receive treatment with tamoxifen for up to 5 years or until menopause at which time women may switch to the AIs. [6]

Treatment with adjuvant endocrine therapy (AET: aromatase inhibitors and/or tamoxifen) has been demonstrated to reduce the risk of subsequent breast cancer and the rate of mortality versus non-users in both clinical trials and in diverse population-based cohorts of women in clinical practice.[4,7–10] Compared with non-users, the reduction in subsequent breast cancer risk ranges from 40% to 66% across the AET groups depending on the degree of adherence.[9] Treatment with tamoxifen for 5 years has been shown to reduce the rate of recurrence by 39% throughout the first decade, and reduces breast cancer mortality by about one-third throughout the first 15 years.[10] However, women with a prescription benefit plan who discontinued AET early, were non-adherent, had a significantly higher mortality rate compared with those who finished the full course of therapy.[11] Thus, this suggests that improvements in adherence rates to AET can reduce the morbidity and mortality of women with ER+ breast cancer.

Despite the improvement in disease prognosis among patients treated with AET, approximately 21–50% of patients are non-adherent within 4–5 years.[12] In a retrospective longitudinal study, only 72–81% of patients were adherent (MPR 80%) to anastrozole after 1 year with the mean percentage of adherent patients decreasing over a 3-year period.[13]

While studies have examined the association between co-payments and adherence to AET, they do not include out-of-pocket costs such as the coinsurance or deductibles paid by the patient at the time of a prescription fill for AET, do not control for other out-of-pocket costs, and/or they examine women anytime during AET treatment rather than during the first year following breast cancer diagnosis and treatment.[14–17] Therefore, we sought to measure 1-year adherence to AET among women diagnosed and surgically treated with breast cancer who initiate AET within the first year in a large commercially insured population and to determine, *a priori*, the association between combined out-of-pocket costs for AET medication and adherence.

MATERIALS AND METHODS

Data Source

We conducted a retrospective cohort study using longitudinal inpatient, outpatient, and prescription claims data from a nation-wide, employer-based, commercially insured population in the United States. We used the Truven Health Analytics MarketScan® Commercial Claims and Encounters Databases from January 1, 2007 to December 31, 2011. The MarketScan® databases capture person-specific clinical utilization, expenditures, and enrollment across inpatient, outpatient, and prescription drug services. All data were de-identified in accordance with the Health Insurance Portability and Accountability Act requirements. Study procedures were conducted in accordance with the ethical standards of the institutional review board at the University of Washington.

Sample Selection

We identified women under the age of sixty-four with at least one prescription claim for an AI, or tamoxifen between January 1, 2008 and December 31, 2010 (Figure 1). Initiation of AET was defined as no AET prescription claims for at least six months before the first claim (index claim). Next, women were included in the cohort if they were diagnosed and surgically treated for breast cancer within twelve months prior to the index claim. Although AET treatment is recommended for up to 5 years, we were interested adherence after first initiation as a critical period for intervention. Breast cancer diagnosis was defined as a diagnostic International Classification of Diseases, Ninth Revisions, Clinical Modification code (ICD-9-CM) for ductal in situ carcinoma (ICD-9-CM: 233.0), primary invasive breast cancer (ICD-9-CM: 174.0 to 174.9) or primary invasive breast cancer with axillary lymph node involvement (ICD-9-CM: 196.0–196.3, 196.5–196.6, or 196.8–196.9) in inpatient records. Surgical treatment was defined as an ICD-9-CM code or Current Procedural Terminology (CPT) code (4th Edition) for bilateral mastectomy, mastectomy, or breast conserving surgery/lumpectomy.[18–20] We restricted our sample to women continuously enrolled in a health plan that included prescription drug coverage for at least six months prior to and 12 months after the index claim. We excluded women with a diagnosis of multiple primary cancers, metastatic breast cancer to distant organs, or breast cancer recurrence any time prior to initiation and during the study period.

Outcome—The primary outcome was medication adherence to AET calculated using the proportion of days covered (PDC).[21] We assumed women did not take more than one AET medication at a time.[22] PDC was calculated based on the fill dates and the number of days' supply for each prescription. The numerator was the total number of days covered by the prescription fill during the 12-month study period. We created coverage periods to reflect the dates that were encompassed by each prescription fill. We shifted the start date of each period so that women did not have overlapping days of coverage. We assumed that women did not take the refilled medication before exhausting the previous prescription [23]. The denominator was 365, the number of days between the index claim and the end of the follow-up study period (12 months after the index claim). The ratio was multiplied by 100 to obtain the percentage of the proportion of days covered. We categorized patients as being adherent if the PDC was 80% or greater.[24]

Time to discontinuation—We examined the time to AET discontinuation among patients considered non-adherent (PDC<80%). We assumed that a woman discontinued AET if she went at least four consecutive months (>120 days) without medication.[13] A woman was considered to discontinue treatment the month in which she filled her last prescription; therefore we could only measure up to eight months.

Out-of-pocket costs for AET—Mean out-of-pocket costs for a 30-day supply of AET medication were defined as the sum of the co-payments, deductibles, and coinsurance paid by the subject at the time that the prescription was filled. Out-of-pocket cost amounts for 60- or 90-day prescriptions were adjusted to 30-day amounts. Out-of-pocket costs for AET were categorized into quintiles of less than $4.99, $5.00 to $9.99, $10.00 to $14.99, $15.00–19.99, and more than $20.00 based on common copayment amounts in multiples of $5 and so that each category represented an equivalent dollar amount and an approximately equal distribution of patients. As a sensitivity analysis for the category cut-points we included a continuous measure of AET out-of-pocket costs to determine if out-of-pocket costs were associated with adherence.

Other out-of-pocket costs—Other out-of-pocket costs paid by the patient at the time services were rendered were calculated for inpatient and outpatient services, and pharmacy medications (excluding AET medication). Other out-of-pocket costs were calculated for each refill period and adjusted to reflect an average 30-day out-of-pocket costs from the index date until the patient no longer had AET medication on-hand, up to 365 days. Other out-of-pocket costs for 30-days were categorized into quintiles of less than $49.99, $50–99.99, $100–149.99, $150–199.99, and greater than $200 so that each category represented an equivalent dollar amount with an approximately even distribution of patients.

Co-morbidities—We used the Elixhauser index to control for comorbidities using inpatient and outpatient diagnoses (IDC-9-CM codes) during the time period prior to the index date.[25] Subjects were assigned a value based on the number of comorbidities.

Additional Subject Characteristics—Subject characteristics were limited to those variables that were available in the MarketScan® Database. Age in years was evaluated categorically (less than 40, 40–49, 50–59, and 60–64 years of age) and a variable to indicate whether subjects used mail or retail pharmacy was calculated based at the index date. We created breast cancer treatment variables for surgery (bilateral mastectomy, mastectomy, or lumpectomy), and the receipt of chemotherapy and/or radiation using ICD-9-CM and CPT codes from inpatient and outpatient claims up to twelve months prior to their first AET prescription fill.[18–20] We assessed whether women had an oophorectomy prior to initiating AET. We included a variable for the duration of time from surgical treatment to the index date (0–3, 4–6, 7–9, and 10–12 months). Pill burden was calculated as the count of unique drug classes filled 90 days prior to the index date. We included a variable for geographic region (Northeast, North Central, South, and West), and health plan type (health maintenance organization, preferred provider organization, other). We determined if women switched AET medication if they filled a prescription for any other AI or tamoxifen different

than the index drug and were categorized as not switched, switched once, or switched 2 or more times.

Statistical Analysis

Unadjusted differences in the percentage of non-adherent (PDC<80%) and adherent (PDC 80%) women were evaluated using the Pearson X^2 test for categorical variables.

We used a multivariate logistic regression model with robust standard error estimates to calculate the odds of being adherent to AET versus being non-adherent in a one-year period. All previously described variables were included in the model and were considered to be clinically significant and potential confounders based on prior studies.[14–17,26] We used the direct substitution method to determine the adjusted risk ratio (ARR) and adjusted risk difference (ARD) since adherence was not considered to be a rare event thus avoiding inappropriately reporting odds ratios, which cannot be properly interpreted as the risk of an event in this setting.[27] The ARR is the ratio of the mean predicted probabilities and is a measure for the probability of adherence for each category of co-payment after controlling for potential confounders. The ARD is the difference of the mean predicted probabilities and represents differences in the absolute risk of adherence. All analyses were conducted using Stata 13.1 SE (StatCorp™ College Station, TX).

RESULTS

During the 3-year study period, 6,863 women were identified in the MarketScan databases who were 64 years and younger and initiated AET following a diagnosis and surgical treatment of early breast cancer. Among this cohort, 26.1% of patients were non-adherent because they had fewer than 80% of AET medication days covered (PDC<80%) during the first year of therapy.

Table 1 lists characteristics of the study cohort by the proportion of subjects who were adherent to AET medication (PDC 80%). In the cohort, 59% of the patients were between 50–64 years of age. The majority had early breast cancer without lymph node involvement (68%), were enrolled in a PPO health plan (60%), filled prescriptions using a retail pharmacy (84%), received chemotherapy treatment (57%), did not have a pre-existing diagnosis of a major condition (62%), and did not switch AET during the 12 month follow-up period (84%). Half of the patients initially filled a prescription for tamoxifen (51%). The mean out-of-pocket costs for a 30 days' supply of AET medication was $17.10 (SD 22.4) while the mean 30-day out-of-pocket costs for other prescriptions and inpatient and outpatient services was $176.50 (SD: 172.20).

In the unadjusted analysis, adherence to AET was associated with age, treatment with chemotherapy, geographical region, AET drug type, the number of times a patient switched AET medication, the number of prescription drugs filled 90-days prior to index date, and the pharmacy type that the patient used. A greater proportion of patients were less likely to be adherent to AET with increasing out-of-pocket costs for AET medication (p<0.05).

Out-of-Pocket costs for AET medication

The adjusted analysis presented in table 2 are the ARR and ARD of adherence to AET for each of the covariates. On average, copayments accounted for approximately 89% of the total out-of-pocket costs for a 30-days' supply of AET medication, while deductibles and coinsurance accounted for 6% and 5%, respectively. We found that 30-day out-of-pocket cost for AET medication was significantly associated with the adjusted risk of adherence (p<0.001, Table 2). On average, patients with a mean monthly out-of-pocket cost for AET medication between \$10–\$14.99, \$15.00–\$19.99, and \$20 or greater were 6–8% less likely to be adherent to AET compared to patients with an out-of-pocket cost of less than \$4.99, after controlling for covariates (ARR: 0.93; 95% CI, 0.88 to 0.98, ARR: 0.92; 95% CI 0.85–0.98, and ARR: 0.94; 95% CI 0.89–0.99, respectively). We observed the association for each category of out-of-pocket costs for AET medication except for patients with a \$5.00–\$9.99 out-of-pocket cost for a 30 days' supply of AET medication. However, a sensitivity analysis was performed classifying out-of-pocket costs for AET as a continuous variable and the results were unchanged.

Copayments, deductibles, and coinsurance accounted for 46.3%, 18.6%, and 35.2%% of 30-day out-of-pocket costs for other prescription medication, and inpatient and outpatient services (data not shown). Other out-of-pocket costs were not associated with adherence to AET medication.

Other patient characteristics

Women age 60–64 were more likely to be adherent to AET compared to women less than 39 years (ARR: 1.17, 95% CI: 1.11–1.22). Women in the geographical south (ARR: 0.89, 95% CI 0.85 to 0.93) of the US and the West (ARR: 0.94, 95% CI: 0.89 to 0.99) were significantly less likely to be adherent to AET compared to women in the Northeast. Women who used a mail pharmacy compared to a retail pharmacy for their first AET prescription fill were more likely to be adherent to AET (ARR: 1.15, 95% CI: 1.11 to 1.19). Patients were less likely to be adherent to AET for every increase in pre-existing condition that a woman had (ARR: 0.98, 95% CI: 0.96 to 0.99) and for every time she switched AET medication (2 or more times versus no switching ARR: 0.83, 95% CI: 0.73 to 0.95). Women with 10–12 months between surgical treatment and index claim were less likely to be adherent to AET compare to women with 0–3 months (ARR: 0.91, 95% CI: 0.84 to 0.98).

Time to discontinuation

We examined the time to discontinuation of AET medication among women who were considered non-adherent (PDC<80) (n=1,790). The mean PDC among non-adherent patients (PDC<80) was 50%. Figure 2 depicts the percentage of patients, by month, who went greater than 120 consecutive days without medication, considered to have discontinued AET. Among non-adherent patients, 19.1% discontinued after the first month of AET prescription fill. After 8 months, 46.7% of non-adherent patients discontinued therapy. Of the non-adherent women (PDC<80%), 53.3% were not considered to have discontinued therapy but had intermittent prescription refills throughout the 12-month study period, although not enough to have greater than 80% of medication on-hand. Patients who discontinued therapy during the study period had a mean 30-day out-of-pocket costs for

AET of $19.47, compared to $18.04 for women who were non-adherent but who had not discontinued therapy.

DISCUSSION

In this study, we found that 73.9% of women who initiated AET after a diagnosis of early breast cancer had filled prescriptions to have pills for at least 292 days (80%) over the first year. We observed that women with higher out-of-pocket costs for AET medication fills was significantly associated with a 6–8% lower likelihood of adherence to AET among a privately insured cohort of women with a prescription drug plan. The fact that low adherence is influenced by out-of-pocket costs for AET medication is important because low adherence to AET is associated with 10–49% higher breast cancer-specific mortality compared to women who are adherent.[11,28]

The finding on the association between higher out-of-pocket costs for AET and lower risk of adherence is similar to other retrospective cohort studies that have found, on average, co-payments decrease the odds of adherence to AI's or tamoxifen.[13,14,16,17] These studies, however, examined the effect of co-payments and not total out-of-pocket costs. In our study, we found that 5–6% of the total out-of-pocket costs were from coinsurance and deductibles at the time of AET prescription fill. We found that patients with a categorical out-of-pocket costs for AET medication greater than or equal to $10 was associated with a lower odds of adherence compared to patients with less than $4.99 out-of-pocket costs. In an exploratory analysis (results not shown) we observed that patients with less than $10 out-of-pocket costs for AET medication was associated with filling a prescription for tamoxifen versus an aromatase inhibitor and with filling a prescription using mail order pharmacies versus retail pharmacies. Tamoxifen drug costs tended to be cheaper than the aromatase inhibitors because a generic form of tamoxifen became available in 2002, prior to the study period. Studies suggest that the side-effects from tamoxifen may be more manageable compared to the side-effects from the aromatase inhibitors.[29,30] Filling a prescription using mail order pharmacies may be more convenient and patients can often order in larger supplies (e.g. 90 days) which is more economical.[31] However, despite these differences between the two groups of out-of-pocket costs, in a sensitivity analysis, a continuous variable for a $1 increase for a 30-day supply of AET medication was statistically associated with a decrease in the odds of adherence after adjusting for all other covariates.

In our study we did not find that out-of-pocket costs for other prescription pharmacy, and inpatient or outpatient services was associated with adherence. Sedjo and colleagues found that other out-of-pocket costs were associated with adherence to AET, however, out-of-pocket costs were included as the sum for the entire 12-month follow-up period even if women had discontinued filling prescriptions for AET, likely over-inflating the association with adherence to AET medication.[17] In our study we calculated other out-of-pocket costs as a 30-day average limited to the time that women had filled prescriptions for AET medication. This is important since over one-quarter of the cohort were non-adherent.

Our findings on adherence rates are consistent with reports using similar claims-based methodology among insured women which found 12-month adherence to AET were ranged

between 72–81% (MPR 80%).[13,15–17] We found that discontinuation among non-adherers (PDC<80%) was greatest after the first month of initiation (19%) and then decreased to 4%–7% per month, thereafter. This trend is similar to a study by Partridge and colleagues who found that the greatest percent of women who went greater than 120 days without medication was after the first month, although continued to increase thereafter.[13] Additionally, we found that among non-adherers (PDC<80%), over half of the patients (53.3%) had intermittently filled prescriptions throughout the 12-month follow-up but did not go more than 120 days without medication on-hand. Thus, in addition to pharmacists and oncologists encouraging women to regularly fill prescriptions, structural factors such as automated reminder calls particularly after the first month of AET initiation may increase subsequent refills.

Similar to other research studies, we found that, on average, older women, women who used mail order versus retail pharmacies, and women with fewer comorbidities was associated with a higher probability of adherence.[13,15–17] Studies have also found that patients who experience side effects from AET are more likely to be non-adherent.[7,8,12,32] In our study, there was a 15% decreased probability of adherence among women who switched AET medication once compared to those that did not switch (p<0.001). In a chart review study, approximately 84% of breast cancer survivors who took anastrozole switched to another AI due to side effects.[33] Thus, medication switching may partially be correlated with medication side effects. We attempted to control for side effects from initial breast cancer treatment by including the time from surgery to initiation and found that the more time that elapsed, the more the probability of adherence decreased. This is an important finding because women who allow more time to elapse may have greater side-effects from initial treatment and leads them to delay initiating AET medication.

Our study had limitations. The measure of adherence using pharmacy claims is how much medication a woman has procured over a 12-month period, but may not reflect actual medication consumption and does not reflect issues such as lost medications. Clinical and prognostic factors such as date of diagnosis, stage of disease, and ER+ status are not readily available from claims and billing data, therefore we had to develop procedural and diagnostic algorithms for these measures which may have misclassified patients. We do not know from claims if each woman in our sample had an appropriate indication for AET treatment. We assumed that if a woman filled a prescription for AET following treatment for a newly diagnosed non-metastatic breast cancer, she met NCCN treatment recommendations for AET and is likely to have ER+ breast cancer. It is possible that the index date we identified may not have been their first AET fill, although we restricted our sample to women with no evidence of recurrent breast cancer and no evidence of prior AET use. Several potential predictors such as socioeconomic factors and race/ethnicity were not available. Out-of-pocket costs for AET may be a surrogate for SES factors, however, we did not find a significant difference between other out-of-pocket costs and adherence to AET as we did with out-of-pocket costs specific to AET medication therefore limiting the plausibility of this assumption. Unmeasured factor(s) such as side effects from initial treatment and AET medication may also be a contributing factor to the findings, however our inclusion of a variable to measure time from surgery to first prescription refill and medication switching may limit the impact of treatment side effects on adherence. Finally,

all of the women in the study were commercially insured in a plan that offered prescription coverage and are likely healthier and younger than the general population of breast cancer patients.

Our findings have important implications. High out-of-pocket cost for AET medication are significantly associated with non-adherence and may put patients at an increased risk of cancer recurrence and increased morbidity if they cannot access medication.[4,5,9,11] Further research should focus on interventions to lower out-of-pocket costs for AET medication by exploring the role that pharmacists can play by identifying patients that belong to plans that have high cost sharing and make recommendations to select generic versus brand name drugs that are in alternate drug plan tiers.[14] Even among commercially insured patients with a prescription drug plan in the United States, adherence to AET is suboptimal. Efforts to lower the out-of-pocket costs for AET medication could significantly improve adherence.

Acknowledgments

References

1. American Cancer Society. Breast Cancer Facts & Figures 2013–2014. Atlanta, GA: American Cancer Society; 2013.

2. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014; 64(1): 52–62. [PubMed: 24114568]

3. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010; 28(23):3784–3796. [PubMed: 20625130]

4. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381(9869):805–816. [PubMed: 23219286]

5. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010; 28(3):509–518. [PubMed: 19949017]

6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast Cancer. 2014. Version 2.2015:www.nccn.org. Accessed May, 2015

7. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350(11):1081–1092. [PubMed: 15014181]

8. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365(9453):60–62. [PubMed: 15639680]

9. Haque R, Ahmed SA, Fisher A, et al. Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer. Cancer Med. 2012; 1(3):318–327. [PubMed: 23342281]

10. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378(9793):771–784. [PubMed: 21802721]

11. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011; 126(2):529–537. [PubMed: 20803066]

12. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology. 2006; 71(1–2):1–9. [PubMed: 17344666]

13. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008; 26(4):556–562. [PubMed: 18180462]

14. Hershman DL, Tsui J, Meyer J, et al. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. J Natl Cancer Inst. 2014; 106(11)

15. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010; 28(27):4120–4128. [PubMed: 20585090]

16. Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011; 29(18):2534–2542. [PubMed: 21606426]

17. Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat. 2011; 125(1):191–200. [PubMed: 20495864]

18. Gross CP, Smith BD, Wolf E, Andersen M. Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer. 2008; 112(4):900–908. [PubMed: 18181101]

19. Mandelblatt JS, Kerner JF, Hadley J, et al. Variations in breast carcinoma treatment in older medicare beneficiaries: is it black or white. Cancer. 2002; 95(7):1401–1414. [PubMed: 12237908]

20. Srokowski TP, Fang S, Duan Z, et al. Completion of adjuvant radiation therapy among women with breast cancer. Cancer. 2008; 113(1):22–29. [PubMed: 18442124]

21. Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009; 43(1):36–44. [PubMed: 19126828]

22. Sherman BW, Sekili A, Prakash ST, Rausch CA. Physician-specific variation in medication adherence among diabetes patients. Am J Manag Care. 2011; 17(11):729–736. [PubMed: 22084892]

23. RS L. Using arrays to calculate medication utilization. 2007

24. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002; 288(4):455–461. [PubMed: 12132975]

25. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998; 36(1):8–27. [PubMed: 9431328]

26. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012; 134(2):459–478. [PubMed: 22689091]

27. Kleinman LC, Norton EC. What's the Risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression. Health Serv Res. 2009; 44(1):288–302. [PubMed: 18793213]

28. McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008; 99(11):1763–1768. [PubMed: 18985046]

29. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011; 103(17):1299–1309. [PubMed: 21743022]

30. Carlson RW, Hudis CA, Pritchard KI, Oncology NCCNBCCPGi, Inhibitors ASoCOTAotUoA, Cancer SGIECotPToEB. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw. 2006; 4(10):971–979. [PubMed: 17112447]

31. Valluri S, Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL. Drug utilization and cost in a Medicaid population: a simulation study of community vs. mail order pharmacy. BMC Health Serv Res. 2007; 7:122. [PubMed: 17663768]

32. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001; 19(2):322–328. [PubMed: 11208822]

33. Schwartzberg LS, Cobb P, Senecal F, et al. Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer. Breast. 2009; 18(2):78–83. [PubMed: 19342237]

Figure 1.
Study cohort selection and subject exclusion.

Figure 2. Proportion of non-adherent patients who went greater than 120 consecutive days without medication on-hand, considered to have discontinued adjuvant endocrine therapy, (n=1,790)

*By definition, patients were considered to have discontinued AET medication if they had greater than 120 days without medication on-hand and therefore patients could only be considered to have discontinued therapy up to the 8th month after initial prescription fill. Patients were considered to have discontinued AET medication the month that they last filled medication.

Table 1

Baseline Characteristics of Women Newly Diagnosed with Early Breast Cancer Who Initiate Adjuvant Endocrine Therapy (n=6,863)

	Total cohort		Adherent rate (PDC 80%) by category	
	%	n	%	p-value±
Overall cohort	100	6863	73.8	
Breast Cancer				<0.01
DCIS	1.9	127	69.3	
Early breast cancer	68.2	4683	73.0	
Breast cancer with axillary lymph node involvement	29.9	2053	76.3	
Age, years				<0.001
18–39	8.0	552	64.3	
40–49	33.4	2292	71.4	
50–59	41.3	2834	75.7	
60–64	17.3	1185	79.0	
Comorbidities				
Hypertension	18.1	1240	74.0	0.92
Chronic pulmonary disease	5.6	386	72.8	0.61
Diabetes, uncomplicated	4.8	330	69.7	0.07
Hypothyroidism	6.6	455	75.8	0.34
Obesity	5.1	350	75.4	0.51
Fluid and electrolyte disorders	2.6	180	68.3	0.08
Deficiency anemias	3.7	254	68.9	0.06
Depression	4.4	303	69.3	0.06
Elixhauser Conditions Composite				0.31
0	61.5	4219	74.4	
1	25.4	1744	73.9	
2	8.3	568	73.6	
3	3.0	207	69.6	
4	1.8	125	68.0	
Surgery				0.65
Mastectomy	28.6	1963	74.6	
Bilateral mastectomy	4.6	318	74.8	
Breast Conservative Surgery/Lumpectomy	66.8	4582	73.6	
Time from surgical treatment to first AET fill, months				0.12
0–3	39.2	2689	74.3	
4–6	30.7	2105	74.9	
7–9	23.1	1588	73.2	
10–12	7.0	481	69.9	
Chemotherapy	57.1	3920	75.1	0.01

	Total cohort		Adherent rate (PDC 80%) by category	
	%	n	%	p-value±
Radiation Therapy	33.6	2303	74.4	0.50
Oophorectomy	2.2	152	72.4	0.67
Health Plan Type				0.12
HMO	18.2	1246	71.6	
PPO	60.1	4125	74.5	
Other	21.7	1492	74.3	
Initiation year of AET				0.04
2008	31.6	2165	72.8	
2009	34.7	2383	73.1	
2010	33.7	2315	75.8	
Region				<0.001
Northeast	16.8	1153	78.8	
North Central	21.0	1440	76.5	
South	40.8	2801	70.1	
West	20.6	1411	75.1	
Unknown	0.9	58	69.0	
AET drug type at index date, % (n)				<0.001
Exemestane	1.9	128	73.4	
Anastrozole	30.0	2057	78.0	
Letrozole	17.0	1166	72.6	
Tamoxifen	51.2	3512	72.0	
Number of times AET medication switched				<0.001
0	83.9	5758	75.9	
1	14.1	966	63.6	
2 or more	2.0	139	65.5	
Pharmacy type at baseline				<0.001
Retail	84.3	5783	72.3	
Mail order	13.5	923	85.5	
Unknown	2.3	157	66.2	
Number of prescriptions filled 90-days prior to the index date				<0.001
0	5.0	340	62.7	
1–5	56.8	3900	74.7	
6–10	31.6	2166	73.8	
Greater than 10	6.7	457	76.4	
Out-of-pocket costs for 30 days' supply of AET medication, $				<0.001
0–4.99	19.0	1306	75.7	
5.00–9.99	29.6	2029	76.4	
10.00–14.99	16.8	1154	70.3	
15.00–19.99	10.1	694	71.6	
20.00 or greater	24.5	1680	73.0	

	Total cohort		Adherent rate (PDC 80%) by category	
	%	n	%	p-value±
Other out-of-pocket costs, 30 day average, $¥				0.60
0–49.99	18.9	1300	73.9	
50–99.99	21.0	1442	75.2	
100–149.99	15.0	1032	73.5	
150–199.99	13.3	910	74.7	
200 or greater	31.8	2179	73.0	

Comorbidities presented were the most prevalent of the 30 Elixhauser conditions among members in the cohort. The Elixhauser comorbidities excludes metastatic cancer and solid tumors without metastasis since these were included as part of the exclusion criteria for cohort entry.

± p-values correspond to the Pearson's Chi square for unadjusted analysis to test for differences between adherent and non-adherent proportions for each categorical variable.

¥ Other out-of-pocket costs include services for outpatient, inpatient, and medications (other than AET) during the follow-up period for which patients had AET medication on-hand.

Table 2

Adjusted risk ratio (AAR) and Adjusted Risk Difference (ARD) of adherence to AET medication among women with breast cancer (n=6,863)

Characteristics	ARR	95% CI			ARD	95% CI		
Out-of-pocket costs for 30 days' supply of AET medication, $								
0–4.99	1.00							
5.00–9.99	1.01	0.97	to	1.05	0.01	−0.03	to	0.04
10.00–14.99	0.93	0.88	to	0.98	−0.05	−0.09	to	−0.01
15.00–19.99	0.92	0.85	to	0.98	−0.06	−0.11	to	−0.02
20.00 or greater	0.94	0.89	to	0.99	−0.04	−0.08	to	0.00
Other out-of-pocket costs, 30 day average, $¥								
0–49.99	1.00							
50–99.99	1.01	0.97	to	1.06	0.02	−0.02	to	0.04
100–149.99	0.98	0.93	to	1.04	−0.01	−0.05	to	0.03
150–199.99	1.01	0.96	to	1.06	0.00	−0.03	to	0.04
200 or greater	0.99	0.95	to	1.04	0.00	−0.04	to	0.03
Breast Cancer								
DCIS	1.00							
Early breast cancer	1.04	0.94	to	1.16	0.04	−0.05	to	0.11
Breast cancer with axillary lymph node involvement	1.09	0.99	to	1.19	0.06	−0.01	to	0.13
Age, years								
18–39	1.00							
40–49	1.08	1.03	to	1.13	0.06	0.03	to	0.09
50–59	1.15	1.09	to	1.21	0.10	0.07	to	0.14
60–64	1.17	1.11	to	1.22	0.12	0.08	to	0.16
Health Plan Type								
HMO	1							
PPO	1.01	0.97	to	1.05	0.01	−0.02	to	0.04
Other	0.99	0.95	to	1.04	0.01	−0.04	to	0.03
Initiation year of AET								
2008	1.00							
2009	1.00	0.96	to	1.03	0.00	−0.03	to	0.02

Characteristics	ARR	95% CI		ARD	95% CI	
2010	1.03	0.99	to 1.06	0.02	-0.01	to 0.05
Region						
Northeast	1.00					
North Central	0.96	0.91	to 1.01	-0.03	-0.07	to 0.01
South	0.89	0.85	to 0.93	-0.08	-0.12	to -0.05
West	0.94	0.89	to 0.99	-0.04	-0.08	to -0.01
Unknown	0.90	0.75	to 1.07	-0.08	-0.20	to 0.04
AET drug type at index date, % (n)						
Exemestane	1.00					
Anastrozole	1.03	0.93	to 1.13	0.02	-0.05	to 0.09
Letrozole	0.98	0.88	to 1.09	-0.02	-0.10	to 0.06
Tamoxifen	0.97	0.88	to 1.08	-0.02	-0.10	to 0.06
Pharmacy type at baseline						
Retail	1					
Mail order	1.15	1.11	to 1.19	0.11	0.08	to 0.14
Unknown	0.94	0.84	to 1.04	-0.05	-0.12	to 0.03
Number of times AET medication switched						
0	1.00					
1	0.84	0.80	to 0.89	-0.12	-0.15	to -0.09
2 or more	0.83	0.73	to 0.95	-0.12	-0.21	to -0.04
Surgery						
Mastectomy	1.00					
Bilateral mastectomy	1.01	0.95	to 1.08	0.01	-0.04	to 0.06
Breast Conservative Surgery/Lumpectomy	0.99	0.96	to 1.02	-0.01	-0.03	to 0.02
Time from surgical treatment to first AET fill, months						
0–3	1.00					
4–6	0.97	0.93	to 1.01	-0.03	-0.05	to 0.00
7–9	0.94	0.89	to 0.99	-0.05	-0.08	to -0.01
10–12	0.91	0.84	to 0.98	-0.07	-0.12	to -0.02
Chemotherapy (yes versus no)	1.08	1.04	to 1.12	0.06	0.03	to 0.09
Radiation Therapy (yes versus no)	0.99	0.96	to 1.03	-0.01	-0.03	to 0.02

Characteristics	ARR		95% CI		ARD		95% CI	
Oophorectomy (yes versus no)	1.02	0.94	to	1.12	0.02	−0.05	to	0.08
Number of prescriptions filled 90-day prior to follow-up period (continuous)	1.01	1.00	to	1.01	0.00	0.00	to	0.01
Elixhauser Conditions Composite (continuous)	0.98	0.96	to	0.99	−0.02	−0.03	to	−0.01

*
Indicates the p-value for a test of trend using the continuous variable for mean 30-day out of pocket costs for AET medication, F-test statistic with all dummy variables

¥
Other out-of-pocket costs include services for outpatient, inpatient, and medications (other than AET) during the follow-up period for which patients had AET medication on-hand.